S1 Biopharma is developing first-in-class drugs to treat sexual dysfunction in both women and men. The company’s therapies are non-hormonal, acting on the sexual centers of the brain by restoring the natural balance of key neurotransmitters. The scientific basis for the development of these drugs is the Kinsey dual control model, which states that sexual arousal and associated behavior are modulated by mechanisms in the brain that involve the balance of excitatory and inhibitory systems through neurotransmitters.
Orexa™ and Lorexys™ are novel pharmacologic entities clinically designed to the highest safety standards for the treatment of erectile dysfunction (ED) and hypoactive sexual desire disorder (HSDD), the most common of the female sexual disorders. The oral formulations, Orexa formulated for ED, Lorexys for HSDD, act on the central nervous system (CNS) to deliver therapeutic benefits and can be used as either a stand-alone or as an adjunct to other therapies for the treatment of ED and HSDD.
S1 has follow-on therapies S1B-307 for Orgasmic Disorder developed to lower the threshold to achieve orgasm and improve satisfaction, and S1B-3006 for treatment-resistant cases of sexual dysfunction (SD) in men and women.